MAP kinases couple multiple functions of human progesterone receptors: Degradation, transcriptional synergy, and nuclear association

Journal of Steroid Biochemistry and Molecular Biology

Volumn 85, Issue 2-5, 2003, Pages 147-157

  Qiu, Ming ^a   Lange, Carol A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Breast cancer; Mitogen activated protein kinase; Phosphorylation; Progesterone receptors; Ubiquitin

Indexed keywords

GESTAGEN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEPTIDE; PROGESTERONE RECEPTOR; PROTEASOME; SERINE; STEROID HORMONE; STEROID RECEPTOR; UBIQUITIN;

BREAST CARCINOMA; CANCER GROWTH; CELLULAR DISTRIBUTION; CHEMICAL MODEL; CONFERENCE PAPER; DOWN REGULATION; ENZYME ACTIVITY; HORMONE RESISTANCE; HORMONE RESPONSE; HUMAN; IN VITRO STUDY; NUCLEAR LOCALIZATION SIGNAL; PHOSPHORYLATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 0042978662     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00221-8     Document Type: Conference Paper

References (72)

1. Encarnacion C.A., Ciocca S.R., McGuire W.L., Clark G.M., Fuqua S.A.W., Osborne C.K. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26(3):1993;237-246.
2. Nicholson R.I., McClelland R.A., Gee J.M., Manning D.L., Cannon P., Robertson J.F., Ellis I.O., Blamey R.W. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat. 29(1):1994;117-125.
3. Elledge R.M., McGuire W.L., Osborne C.K. Prognostic factors in breast cancer. Semin. Oncol. 19(3):1992;244-253.
4. Krusekopf S., Chauchereau A., Milgrom E., Henderson D., Cato A.C. Co-operation of progestational steroids with epidermal growth factor in activation of gene expression in mammary tumor cells. J. Steroid Biochem. Mol. Biol. 40(1-3):1991;239-245.
5. Modiano J.F., Kokai Y., Weiner D.B., Pykett M.J., Nowell P.C., Lyttle C.R. Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line. J. Cell. Biochem. 45(2):1991;196-206.
6. Chrysogelos S.A., Dickson R.B. EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res. Treat. 29(1):1994;29-40.
7. Murphy L.J., Sutherland R.L., Stead B., Murphy L.C., Lazarus L. Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res. 46(2):1986;728-734.
8. Sarup J.C., Rao K.V., Fox C.F. Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor. Cancer Res. 48(18):1988;5071-5078.
9. Lange C.A., Richer J.K., Shen T., Horwitz K.B. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J. Biol. Chem. 273(47):1998;31308-31316.
10. Richer J.K., Lange C.A., Manning N.G., Owen G., Powell R., Horwitz K.B. Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J. Biol. Chem. 273(47):1998;31317-31326.
11. Lange C.A., Richer J.K., Horwitz K.B. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol. Endocrinol. 13(6):1999;829-836.
12. Hunter T. Signaling - 2000 and beyond. Cell. 100(1):2000;113-127.
13. Lange-Carter C.A., Johnson G.L. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science. 265(5177):1994;1458-1461.
14. Minden A., Lin A., McMahon M., Lange-Carter C., Derijard B., Davis R.J., Johnson G.L., Karin M. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science. 266(5191):1994;1719-1723.
15. Shen T., Horwitz K.B., Lange C.A. Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent downregulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol. Cell. Biol. 21(18):2001;6122-6131.
16. Johnson N.L., Gardner A.M., Diener K.M., Lange-Carter C.A., Gleavy J., Jarpe M.B., Minden A., Karin M., Zon L.I., Johnson G.L. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. J. Biol. Chem. 271(6):1996;3229-3237.
17. Dickson R.B., Johnson M.D., Bano M., Shi E., Kurebayashi J., Ziff B., Martinez-Lacaci I., Amundadottir L.T., Lippman M.E. Growth factors in breast cancer: mitogenesis to transformation. J Steroid Biochem. Mol. Biol. 43(1-3):1992;69-78.
18. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., Davis R.J. JNK1: a protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-jun activation domain. Cell. 76(6):1994;1025-1037.
19. Dubik D., Dembinski T.C., Shiu R.P.C. Stimulation of c-myc oncogene expression associated with estrogen induced proliferation of human breast cancer cells. Cancer Res. 47:1987;6517-6521.
20. Wong M.S., Murphy L.C. Differential regulation of c-myc by progestins and antiestrogens in T47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 39(1):1991;39-44.
21. Musgrove E.A., Sutherland R.L. Effects of the progestin antagonist Ru 486 on T47D breast cancer cell cycle kinetics and cell cycle regulatory genes. Biochem. Biophys. Res. Commun. 195(3):1993;1184-1190.
22. Telang N.T., Osborne M.P., Sweterlitch L.A., Narayaman R. Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell. Regul. 1(11):1990;863-872.
23. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H.et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270(5241):1995;1491-1494.
24. Lange C.A., Shen T., Horwitz K.B. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc. Natl. Acad. Sci. U.S.A. 97(3):2000;1032-1037.
25. Groshong S.D., Owen G.I., Grimison B., Schauer I.E., Todd M.C., Langan T.A., Sclafani R.A., Lange C.A., Horwitz K.B. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(KIP1). Mol. Endocrinol. 11(11):1997;1593-1607.
26. Haraguchi S., Good R.A., Engelman R.W., Greene S., Day N.K. Prolactin, epidermal growth factor or transforming growth factor-alpha activate a mammary cell-specific enhancer in mouse mammary tumor virus-long terminal repeat. Mol. Cell. Endocrinol. 129(2):1997;145-155.
27. Knotts T.A., Orkiszewski R.S., Cook R.G., Edwards D.P., Weigel N.L. Identification of a phosphorylation site in the hinge region of human progesterone receptor and additional amino-terminal phosphorylation sites. J. Biol. Chem. 276(11):2001;8475-8483.
28. Rao K.V., Peralta W.D., Greene G.L., Fox C.F. Cellular progesterone receptor phosphorylation in response to ligands activating protein kinases. Biochem. Biophys. Res. Commun. 146(3):1987;1357-1365.
29. Takimoto G., Horwitz K. Progesterone receptor phosphorylation - complexities in defining a functional role. Trends Endocrinol. Metab. 4:1993;1-7.
30. Weigel N.L. Steroid hormone receptors and their regulation by phosphorylation. Biochem. J. 319(3):1996;657-667.
31. Zhang Y., Beck C.A., Poletti A., Edwards D.P., Weigel N.L. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J. Biol. Chem. 269(49):1994;31034-31040.
32. Lee H., Jiang F., Wang Q., Nicosia S.V., Yang J., Su B., Bai W. MEKK1 activation of human estrogen receptor-alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells (in process citation). Mol. Endocrinol. 14(11):2000;1882-1896.
33. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18(3):1999;813-822.
34. Sivaraman V.S., Wang H., Nuovo G.J., Malbon C.C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest. 99(7):1997;1478-1483.
35. Lange-Carter C.A., Pleiman C.M., Gardner A.M., Blumer K.J., Johnson G.L. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science. 260(5106):1993;315-319.
36. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276(38):2001;35684-35692.
37. Dace A., Zhao L., Park K.S., Furuno T., Takamura N., Nakanishi M., West B.L., Hanover J.A., Cheng S. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc. Natl. Acad. Sci. U.S.A. 97(16):2000;8985-8990.
38. Salghetti S.E., Kim S.Y., Tansey W.P. Destruction of myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize myc. EMBO J. 18(3):1999;717-726.
39. Skowyra D., Craig K.L., Tyers M., Elledge S.J., Harper J.W. F-box proteins are receptors that recruit phosphorylated substrates to the scf ubiquitin-ligase complex. Cell. 91(2):1997;209-219.
40. Yaglom J., Linskens M.H., Sadis S., Rubin D.M., Futcher B., Finley D. P34cdc28-mediated control of Cln3 cyclin degradation. Mol. Cell Biol. 15(2):1995;731-741.
41. Salghetti S.E., Muratani M., Wijnen H., Futcher B., Tansey W.P. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. U.S.A. 97(7):2000;3118-3123.
42. Glotzer M., Murray A.W., Kirschner M.W. Cyclin is degraded by the ubiquitin pathway. Nature. 349(6305):1991;132-138. (see comments).
43. King R.W., Glotzer M., Kirschner M.W. Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates. Mol. Biol. Cell. 7(9):1996;1343-1357.
44. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr. Opin. Cell Biol. 9(6):1997;788-799.
45. Pagano M. Cell cycle regulation by the ubiquitin pathway. FASEB J. 11(13):1997;1067-1075.
46. Fenteany G., Standaert R.F., Lane W.S., Choi S., Corey E.J., Schreiber S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science. 268(5211):1995;726-731.
47. Qiu M., Olsen A., Faivre E., Horwitz K.B., Lange C.A. Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol. Endocrinol. 17:2003;628-642.
48. Takimoto G.S., Hovland A.R., Tasset D.M., Melville M.Y., Tung L., Horwitz K.B. Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors. J. Biol. Chem. 271(23):1996;13308-13316.
49. Moore M.R., Zhou J.L., Blankenship K.A., Strobl J.S., Edwards D.P., Gentry R.N. A sequence in the 5′ flanking region confers progestin responsiveness on the human c-myc gene. J. Steroid Biochem. Mol. Biol. 62(4):1997;243-252.
50. Musgrove E.A., Lee C.S., Sutherland R.L. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor-alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol. Cell. Biol. 11(10):1991;5032-5043.
51. McNally J.G., Muller W.G., Walker D., Wolford R., Hager G.L. The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science. 287(5456):2000;1262-1265.
52. Rubin D.M., Coux O., Wefes I., Hengartner C., Young R.A., Goldberg A.L., Finley D. Identification of the Gal4 suppressor Sug1 as a subunit of the yeast 26S proteasome. Nature. 379(6566):1996;655-657.
53. Russell S.J., Sathyanarayana U.G., Johnston S.A. Isolation and characterization of Sug2. A novel ATPase family component of the yeast 26S proteasome. J. Biol. Chem. 271(51):1996;32810-32817.
54. Swaffield J.C., Melcher K., Johnston S.A. A highly conserved ATPase protein as a mediator between acidic activation domains and the TATA-binding protein. Nature. 374(6517):1995;88-91.
55. Weeda G., Rossignol M., Fraser R.A., Winkler G.S., Vermeulen W., van't Veer L.J., Ma L., Hoeijmakers J.H., Egly J.M. The XPB subunit of repair/transcription factor TFIIH directly interacts with Sug1, a subunit of the 26S proteasome and putative transcription factor. Nucleic Acids Res. 25(12):1997;2274-2283.
56. Imhof M.O., McDonnell D.P. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol. Cell. Biol. 16(6):1996;2594-2605.
57. Nawaz Z., Lonard D.M., Smith C.L., Lev-Lehman E., Tsai S.Y., Tsai M.J., O'Malley B.W. The angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell. Biol. 19(2):1999;1182-1189.
58. Kaul S., Blackford J.A. Jr., Cho S., Simons S.S. Jr. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J. Biol. Chem. 277(15):2002;12541-12549.
59. Davie J.R., Murphy L.C. Level of ubiquitinated histone H2B in chromatin is coupled to ongoing transcription. Biochemistry. 29(20):1990;4752-4757.
60. Davie J.R., Murphy L.C. Inhibition of transcription selectively reduces the level of ubiquitinated histone H2B in chromatin. Biochem. Biophys. Res. Commun. 203(1):1994;344-350.
61. Salghetti S.E., Caudy A.A., Chenoweth J.G., Tansey W.P. Regulation of transcriptional activation domain function by ubiquitin. Science. 293(5535):2001;1651-1653.
62. Lonard D.M., Nawaz Z., Smith C.L., O'Malley B.W. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell. 5(6):2000;939-948.
63. Clemm D.L., Sherman L., Boonyaratanakornkit V., Schrader W.T., Weigel N.L., Edwards D.P. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol. Endocrinol. 14(1):2000;52-65.
64. Zhang Y., Beck C.A., Poletti A., Edwards D.P., Weigel N.L. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol. Endocrinol. 9(8):1995;1029-1040.
65. Bamberger A.M., Bamberger C.M., Gellersen B., Schulte H.M. Modulation of AP-1 activity by the human progesterone receptor in endometrial adenocarcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 93(12):1996;6169-6174.
66. Labriola L., Salatino M., Proietti C.J., Pecci A., Kornblihtt A.R., Charreau E.H., Elidalde P.V. Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires a functional erbB2 and MAPK activation in breast cancer cells. Mol. Cell. Biol. 23(3):2003;1095-1111.
67. Gompel A., Martin A., Simon P., Schoevaert D., Plu-Bureau G., Hugol D., Audouin J., Leygue E., Truc J.B., Poitout P. Epidermal growth factor receptor and c-erbB2 expression in normal breast tissue during the menstrual cycle. Breast Cancer Res. Treat. 38(2):1996;227-235.
68. Horwitz K.B. When tamoxifen turns bad. Endocrinology. 136(3):1995;821-823.
69. Haslam S.Z., Counterman L.J., Nummy K.A. Effects of epidermal growth factor, estrogen, and progestin on DNA synthesis in mammary cells in vivo are determined by the developmental state of the gland. J. Cell. Physiol. 155(1):1993;72-78.
70. Lupu R., Cardillo M., Cho C., Harris L., Hijazi M., Perez C., Rosenberg K., Yang D., Tang C. The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res. Treat. 38(1):1996;57-66.
71. Ross R.K., Paganini-Hill A., Wan P.C., Pike M.C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 92(4):2000;328-332.
72. Sartorius C.A., Groshong S.D., Miller L.A., Powell R.L., Tung L., Takimoto G.S., Horwitz K.B. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by camp. Cancer Res. 54(14):1994;3868-3877.